Vincent Hennemand is the Chief Product & Operations Officer at Sail and an Operating Partner at Flagship Pioneering.  At Sail, he has oversight of all product research and development activities.  Prior to joining Flagship, Vincent was Chief Executive Officer of Covant Therapeutics, an innovative covalent drug discovery company.  He was previously Chief Operating Officer for Intergalactic Therapeutics, where he oversaw all business and science operations for the company. Vincent also previously worked as Senior Vice President and Head of Strategy, Corporate and Business Development as well as Head of the Immuno-Inflammation Unit at Akili Interactive.  Prior to Akili, Vincent worked as Vice President of Strategy, Corporate, and Business Development across a portfolio companies at PureTech Health (the founding institution of Akili), where he also contributed to the company creation group supporting the seed stage of several PureTech portfolio companies, including Vedanta Bio and Sonde Health. Vincent spent a decade in pharma at Sanofi Genzyme, during which he had the opportunity to hold several positions in R&D, General Management, Manufacturing, and Corporate Venture (SGBV), where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments.

Vincent holds an MSc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an MSc in Bioengineering from Georgia Tech, and an MBA from MIT, where he received a Martin Trust Center Fellowship.